SCHEMBL22235239

SCHEMBL22235239

COc1cc2nc(C3CC3)cn2cc1N

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SUV39H2 Q9H5I1 11/20 0.39
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
HSD17B10 Q99714 2/20 0.37
TSHR P16473 1/20 0.37
IRAK4 Q9NWZ3 2/20 0.36
TLR9 Q9NR96 2/20 0.36
TLR7 Q9NYK1 2/20 0.36
PDE10A Q9Y233 1/20 0.34
PSEN1 P49768 1/20 0.33
PSEN2 P49810 1/20 0.33
APH1B Q8WW43 1/20 0.33
NCSTN Q92542 1/20 0.33
APH1A Q96BI3 1/20 0.33
PSENEN Q9NZ42 1/20 0.33
NPC1 O15118 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22235013 0.84 IRAK4 (0.48) SUV39H2KDM4EALDH1A1HPGDHSD17B10
Hydrochloric Acid SCHEMBL22235194 0.83 IRAK4 (0.47) SUV39H2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL22235186 0.82 SUV39H2 (0.41) SUV39H2KDM4EALDH1A1HPGDIRAK4
SCHEMBL24033637 0.78 ALDH1A1 (0.39) SUV39H2KDM4EALDH1A1HPGDHSD17B10
Hydrochloric Acid SCHEMBL31600043 0.76 ALDH1A1 (0.38) SUV39H2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL3299736 0.76 POLB (0.43) SUV39H2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL22498206 0.76 MTOR (0.32) SUV39H2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL22234883 0.76 IRAK4 (0.52) KDM4EALDH1A1HPGDHSD17B10IRAK4
SCHEMBL22234666 0.76 IRAK4 (0.53) IRAK4PSEN1PSEN2APH1BNCSTN
SCHEMBL22498078 0.76 MTOR (0.32) SUV39H2KDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220089592-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS BIOGEN MA INC. 2022-03-24 US disclosed
US-20220089592-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS BIOGEN MA INC. 2022-03-24 US disclosed
EP-3911652-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS Biogen MA Inc. (US) 2021-11-24 EP disclosed
WO-2020150626-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS BIOGEN MA INC. (US) 2020-07-23 WO disclosed
WO-2020150626-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS BIOGEN MA INC. (US) 2020-07-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089592-A1 IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS IRAK4, IRAK2, IRAK1 SUV39H2 2155/4885KDM4E 104/4885ALDH1A1 1657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.